Gaps in translation from trials to practice: Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in atrial fibrillation

Thrombosis and Haemostasis

Volumn 111, Issue 5, 2014, Pages 783-788

  Hylek, Elaine M ^a   Ko, Darae ^a   Cove, Christina L ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN; EDOXABAN; NON VITAMIN K ANTAGONIST ORAL ANTICOAGULANT; PROTHROMBIN COMPLEX; PROTON PUMP INHIBITOR; RIVAROXABAN; UNCLASSIFIED DRUG; WARFARIN; VITAMIN K GROUP;

BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; COGNITIVE DEFECT; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; ENZYME POLYMORPHISM; GASTROINTESTINAL HEMORRHAGE; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; KIDNEY FUNCTION; MEDICATION COMPLIANCE; MEDICATION ERROR; META ANALYSIS (TOPIC); MICROANGIOPATHY; OUTCOME ASSESSMENT; PHYSICAL PHENOMENA; PRIORITY JOURNAL; RACE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; TIME IN THERAPEUTIC RANGE; ANTAGONISTS AND INHIBITORS; ATRIAL FIBRILLATION; CLINICAL TRIAL (TOPIC); COMPLICATION; ORAL DRUG ADMINISTRATION; STROKE; TOTAL QUALITY MANAGEMENT; TRANSLATIONAL RESEARCH;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; CLINICAL TRIALS AS TOPIC; HUMANS; QUALITY IMPROVEMENT; STROKE; TRANSLATIONAL MEDICAL RESEARCH; VITAMIN K;

EID: 84899717079     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH13-12-1032     Document Type: Review

References (59)

1. Nguyen TN, Hilmer SN, Cumming RG. Review of epidemiology and management of atrial fibrillation in developing countries. Int J Cardiol 2013; 167: 2412-2420.
2. Kakkar AK, Mueller I, Bassand JP, et al; GARFIELD Registry Investigators. Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry. PLoS One 2013; 8: e63479.
3. Patel MR, Mahaffey KW, Garg J, et al, and the ROCKET AF Steering Committee for the ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891.
4. Granger CB, Alexander JH, McMurray JJV, et al for the ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-992.
5. Connolly SJ, Ezekowitz MD, Yusuf S, et al, and the RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
6. Giugliano RP, Ruff CT, Braunwald E, et al; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: 2093-2104.
7. Debette S, Markus HS. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. Br Med J 2010; 341: c3666.
8. Rosand J, Hylek EM, O'Donnell HC, Greenberg SM. Warfarin-associated haemorrhage and cerebral amyloid angiopathy: A genetic and pathological study. Neurology 2000; 55: 947-951.
9. Lovelock CE, Cordonnier C, Naka H, et al. Antithrombotic drug use, cerebral microbleeds, and intracerebral haemorrhage. Stroke 2010; 41: 1222-1228.
10. Poels MMF, Vernooij MW, Arfan Ikram M, et al. Prevalence and risk factors of cerebral microbleeds. Stroke 2010; 41: S103-S106.
11. Lip GY, Frison L, Grind M; SPORTIF Investigators. Effect of hypertension on anticoagulated patients with atrial fibrillation. Eur Heart J 2007; 28: 752-759.
12. Paulsen MS, Andersen M, Thomsen JL, et al. Multimorbidity and blood pressure control in 37,651 hypertensive patients from Danish general practice. J Am Heart Assoc 2012; 2: e004531.
13. Andersen UO, Jensen GB. Trends and determinant factors in hypertension control in a population study with 25 years of follow-up. J Hypertens 2010; 28: 1091-1096.
14. Hart RG, Diener HC, Yang S, et al. Intracranial haemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran The RE-LY trial. Stroke 2012; 43: 1511-1517.
15. Hart RG, Benavente O, Pearce LA. Increased risk of intracranial haemorrhage when aspirin is combined with warfarin: A meta-analysis and hypothesis. Cerebrovasc Dis 1999; 9: 215-217.
16. Heidbuchel H, Verhamme P, Alings M, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013; 15: 625-651.
17. Fuster V, Rydén LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2011; 123: e269-367.
18. Delaney JA, Opatrny L, Brophy JM, et al. Drug drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding. CMAJ 2007; 177: 347-351.
19. Hansen ML, Sørensen R, Clausen MT, et al. Risk of bleeding with single, dual, or triple therapy in patients with atrial fibrillation. Arch Intern Med 2010; 170: 1433-1441.
20. Steinberg BA, Kim S, Piccini JP, et al. Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: Insights from the ORBIT-AF Registry. Circulation 2013; 128: 721-728.
21. Fang MC, Go AS, Chang Y, et al. Death and disability from warfarin-associated intracranial and extracranial haemorrhages. Am J Med 2007; 120: 700-705.
22. Budnitz DS, Lovegrove MC, Shehab N, et al. Emergency hospitalisations for adverse drug events in older Americans. N Engl J Med 2011; 365: 2002-2012.
23. Witt DM, Delate T, Garcia DA, et al. Risk of thromboembolism, recurrent haemorrhage, and death after warfarin interruption for gastrointestinal bleeding. Arch Intern Med 2012; 172: 1484-1491.
24. Newton JL. Improving the gastrointestinal tolerability of aspirin in older people. Clinical Interventions in Aging 2006; 1: 33-39.
25. Marshall BJ. Helicobacter pylori. Am J Gastroenterol 1994; 89: S116-128.
26. Goddard AF, James MW, McIntyre AS, et al. Guidelines for the management of iron deficiency anaemia. Gut 2011; 60: 1309-1316.
27. Hohnloser SH, Ziad H, Thomas L, et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 2012; 33: 2821-2830.
28. Eikelboom JW, Connolly SJ, Gao P, et al. Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease. J Stroke Cerebrovasc Dis 2012; 21: 429-435.
29. Fox K, Piccini JP, Wojdyla D, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011; 32: 2387-2394.
30. Kaatz S, Kouides PA, Garcia DA, et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol. 2012; 87 (Suppl 1): S141-145.
31. Guo Y, Wang H, Zhao X, et al. Sequential changes in renal function and the risk of stroke and death in patients with atrial fibrillation. Int J Cardiol 2013; 168: 4678-4684.
32. Reilly PA, Lehr T, Haertter S, et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients in the RE-LY Trial. J Am Coll Cardiol 2013; Epub ahead of print.
33. Paré G, Eriksson N, Lehr T, et al. Genetic determinants of dabigatran plasma levels and their relation to bleeding. Circulation 2013; 127: 1404-1412.
34. Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 2013; 369: 1206-1214.
35. Hylek EM. Dabigatran and mechanical heart valves-Not as easy as we had hoped. N Engl J Med 2013; 369: 1264-1266.
36. Rose AJ, Hylek EM, Ozonoff A, et al. Patientcharacteristics associated with oral anticoagulation control: Results of the Veterans AffaiRs Study to Improve Anticoagulation (VARIA). J Thromb Haemost 2010; 8: 2182-2191.
37. Connolly SJ, Pogue J, Eikelboom J, et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008; 118: 2029-2037.
38. White HD, Gruber M, Feyzi J, et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med 2007; 167: 239-245.
39. Gallagher AM, Setakis E, Plumb JM, et al. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost 2011; 106: 968-977.
40. Witt DW, Delate T, Clark NP, et al. Outcomes and predictors of very stable INR control during chronic anticoagulation therapy. Blood 2009; 114: 952-956.
41. Spall HGC, Wallentin L, Yusuf S, et al. Variation in warfarin dose adjustment practice is responsible for differences in the quality of anticoagulation control between centers and countries: An analysis of patients receiving warfarin in the RE-LY trial. Circulation 2012; 126: 2309-2316.
42. Ageno W, Gallus A, Wittkowsky A, et al. Oral anticoagulant therapy: Antithrombotic therapy and prevention of thrombosis. ACCP evidence-based guidelines (Ninth Edition). Chest 2012; 141 (2 Suppl): e44S-88S.
43. Parker CS, Chen Z, Price M, et al. Adherence to warfarin assessed by electronic pill caps, clinician assessment, and patient reports: results from the IN-RANGE study. J Gen Intern Med 2007; 22: 1254-1259.
44. Kimmel SE, Chen Z, Price M, et al. The influence of patient adherence on anticoagulation control with warfarin: results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study. Arch Intern Med 2007; 167: 229-235.
45. Burroughs VJ, Maxey RW, Levy RA. Racial and ethnic differences in response to medicines: towards individualized pharmaceutical treatment. J Natl Med Assoc 2002; 94: 1-26.
46. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. J Am Med Assoc 2007; 298: 2038-2047.
47. Kramer H, Palmas W, Kestenbaum B, et al. Chronic kidney disease prevalence estimates among racial/ethnic groups: The Multi-Ethnic Study of Atherosclerosis. Clin J Am Soc Nephrol 2008; 3: 1391-1397.
48. Hori M, Matsumoto M, Tanahashi N, et al.; J-ROCKET AF study investigators. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation-the J-ROCKET AF study. Circ J 2012; 76: 2104-2111.
49. Takahashi H, Wilkinson GR, Nutescu EA, et al. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra-and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genomics 2006; 16: 101-110.
50. Perera MA, Cavallari LH, Limdi NA, et al. Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet 2013; 382: 790-796.
51. Keshava C, McCanlies EC, Weston A. CYP3A4 Polymorphisms--Potential risk factors for breast and prostate cancer: A HuGE Review. Am J Epidemiol 2004; 160: 825-841.
52. Diener HC, Eikelboom J, Connolly SJ, et al.; AVERROES Steering Committee and Investigators. Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial. Lancet Neurol 2012; 11: 225-231.
53. Bauersachs R, Berkowitz SD, Brenner B, et al, and the EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499-2510.
54. Büller HR, Prins MH, Lensin AW, et al, and the EINSTEIN-PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366: 1287-1297.
55. Agnelli G, Buller HR, Cohen A, et al; for the AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369: 799-808.
56. Medication Guide Pradaxa. Distributed by Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, CT, Revised: December 2013.
57. Eerenberg ES, Kamphuisen PW, Sijpkens MK, et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124: 1573-1579.
58. Liew A, Eikelboom JW, O'Donnell M, et al. Assessment of anticoagulation intensity and management of bleeding with old and new oral anticoagulants. Can J Cardiol 2013; 29 (7 Suppl): S34-44.
59. Sarode R, Milling TJ Jr, Refaai MA, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation 2013; 128: 1234-1243.